Skip to main content
Erschienen in: Heart and Vessels 1/2023

07.07.2022 | Original Article

Prognostic value of 1,5-anhydro-d-glucitol incorporating syntax score in acute coronary syndrome

verfasst von: Tetsuji Morishita, Hiroyasu Uzui, Yasuhiko Mitsuke, Hiroshi Tada

Erschienen in: Heart and Vessels | Ausgabe 1/2023

Einloggen, um Zugang zu erhalten

Abstract

The utility of adding information on 1,5-anhydro-d-glucitol (1,5-AG), a marker for postprandial hyperglycemia, to a pre-existing scoring system in acute coronary syndrome (ACS) patients is unknown. This retrospective cohort study included 266 ACS patients. The end point was major adverse cardiac and cerebral events (MACCE) through 5 years of follow-up. To evaluate incremental benefits of combining 1,5-AG with the syntax score, we applied time-dependent receiver operating curve (ROC) analysis, net reclassification improvement (NRI), integrated discrimination improvement (IDI) and decision curve analysis (DCA). Temporal changes to the area under time-dependent ROC curves showed that addition of 1,5-AG parameters to syntax score did not provide any incremental value (area under the curve for syntax alone, 0.673 (95% confidence interval (CI), 0.599–0.747) vs. with 1,5-AG combined, 0.671 (95%CI 0.596–0.746; Delong p = 0.65). Incorporating 1,5-AG into syntax score yielded a significant NRI of 0.291 (95%CI 0.015–0.567) and IDI of 0.055 (95%CI 0.018–0.093), while DCA analysis showed the limited net benefit in combination with 1,5-AG and syntax score. 1,5-AG values exhibited significant discriminatory utility for detecting MACCE within the ACS population. However, 1,5-AG levels contributed limited utility beyond syntax score based on time-dependent ROC and DCA analyses.
Trial registration: UMIN000023837.
Literatur
1.
Zurück zum Zitat Cho NH, Shaw JE, Karuranga S, Huang Y, da Rocha Fernandes JD, Ohlrogge AW, Malanda B (2018) IDF diabetes atlas: global estimates of diabetes prevalence for 2017 and projections for 2045. Diabetes Res Clin Pract 138:271–281CrossRef Cho NH, Shaw JE, Karuranga S, Huang Y, da Rocha Fernandes JD, Ohlrogge AW, Malanda B (2018) IDF diabetes atlas: global estimates of diabetes prevalence for 2017 and projections for 2045. Diabetes Res Clin Pract 138:271–281CrossRef
2.
Zurück zum Zitat Gregg EW, Li Y, Wang J, Burrows NR, Ali MK, Rolka D, Williams DE, Geiss L (2014) Changes in diabetes-related complications in the United States, 1990–2010. N Engl J Med 370(16):1514–1523CrossRef Gregg EW, Li Y, Wang J, Burrows NR, Ali MK, Rolka D, Williams DE, Geiss L (2014) Changes in diabetes-related complications in the United States, 1990–2010. N Engl J Med 370(16):1514–1523CrossRef
3.
Zurück zum Zitat Rydén L, Grant PJ, Anker SD, Berne C, Cosentino F, Danchin N, Deaton C, Escaned J, Hammes HP, Huikuri H, Marre M, Marx N, Mellbin L, Ostergren J, Patrono C, Seferovic P, Uva MS, Taskinen MR, Tendera M, Tuomilehto J, Valensi P, Zamorano JL, Achenbach S, Baumgartner H, Bax JJ, Bueno H, Dean V, Erol C, Fagard R, Ferrari R, Hasdai D, Hoes AW, Kirchhof P, Knuuti J, Kolh P, Lancellotti P, Linhart A, Nihoyannopoulos P, Piepoli MF, Ponikowski P, Sirnes PA, Tamargo JL, Torbicki A, Wijns W, Windecker S, De Backer G, Ezquerra EA, Avogaro A, Badimon L, Baranova E, Betteridge J, Ceriello A, Funck-Brentano C, Gulba DC, Kjekshus JK, Lev E, Mueller C, Neyses L, Nilsson PM, Perk J, Reiner Z, Sattar N, Schächinger V, Scheen A, Schirmer H, Strömberg A, Sudzhaeva S, Viigimaa M, Vlachopoulos C, Xuereb RG, Members ATF, (CPG) ECfPG, Reviewers D (2013) ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the task force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of cardiology (ESC) and developed in collaboration with the European association for the study of diabetes (EASD). Eur Heart J 34(39):3035–3087CrossRef Rydén L, Grant PJ, Anker SD, Berne C, Cosentino F, Danchin N, Deaton C, Escaned J, Hammes HP, Huikuri H, Marre M, Marx N, Mellbin L, Ostergren J, Patrono C, Seferovic P, Uva MS, Taskinen MR, Tendera M, Tuomilehto J, Valensi P, Zamorano JL, Achenbach S, Baumgartner H, Bax JJ, Bueno H, Dean V, Erol C, Fagard R, Ferrari R, Hasdai D, Hoes AW, Kirchhof P, Knuuti J, Kolh P, Lancellotti P, Linhart A, Nihoyannopoulos P, Piepoli MF, Ponikowski P, Sirnes PA, Tamargo JL, Torbicki A, Wijns W, Windecker S, De Backer G, Ezquerra EA, Avogaro A, Badimon L, Baranova E, Betteridge J, Ceriello A, Funck-Brentano C, Gulba DC, Kjekshus JK, Lev E, Mueller C, Neyses L, Nilsson PM, Perk J, Reiner Z, Sattar N, Schächinger V, Scheen A, Schirmer H, Strömberg A, Sudzhaeva S, Viigimaa M, Vlachopoulos C, Xuereb RG, Members ATF, (CPG) ECfPG, Reviewers D (2013) ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the task force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of cardiology (ESC) and developed in collaboration with the European association for the study of diabetes (EASD). Eur Heart J 34(39):3035–3087CrossRef
4.
Zurück zum Zitat Gaede P, Lund-Andersen H, Parving HH, Pedersen O (2008) Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 358(6):580–591CrossRef Gaede P, Lund-Andersen H, Parving HH, Pedersen O (2008) Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 358(6):580–591CrossRef
5.
Zurück zum Zitat Gerstein HC, Miller ME, Byington RP, Goff DC, Bigger JT, Buse JB, Cushman WC, Genuth S, Ismail-Beigi F, Grimm RH, Probstfield JL, Simons-Morton DG, Friedewald WT, Group AtCCRiDS (2008) Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 358(24):2545–2559CrossRef Gerstein HC, Miller ME, Byington RP, Goff DC, Bigger JT, Buse JB, Cushman WC, Genuth S, Ismail-Beigi F, Grimm RH, Probstfield JL, Simons-Morton DG, Friedewald WT, Group AtCCRiDS (2008) Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 358(24):2545–2559CrossRef
6.
Zurück zum Zitat Patel A, MacMahon S, Chalmers J, Neal B, Billot L, Woodward M, Marre M, Cooper M, Glasziou P, Grobbee D, Hamet P, Harrap S, Heller S, Liu L, Mancia G, Mogensen CE, Pan C, Poulter N, Rodgers A, Williams B, Bompoint S, de Galan BE, Joshi R, Travert F, Group AC (2008) Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 358(24):2560–2572CrossRef Patel A, MacMahon S, Chalmers J, Neal B, Billot L, Woodward M, Marre M, Cooper M, Glasziou P, Grobbee D, Hamet P, Harrap S, Heller S, Liu L, Mancia G, Mogensen CE, Pan C, Poulter N, Rodgers A, Williams B, Bompoint S, de Galan BE, Joshi R, Travert F, Group AC (2008) Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 358(24):2560–2572CrossRef
7.
Zurück zum Zitat UK Prospective Diabetes Study (UKPDS) Group (1998) Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes. Lancet 352(9131):837–853CrossRef UK Prospective Diabetes Study (UKPDS) Group (1998) Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes. Lancet 352(9131):837–853CrossRef
8.
Zurück zum Zitat Ismail-Beigi F, Craven T, Banerji MA, Basile J, Calles J, Cohen RM, Cuddihy R, Cushman WC, Genuth S, Grimm RH, Hamilton BP, Hoogwerf B, Karl D, Katz L, Krikorian A, O’Connor P, Pop-Busui R, Schubart U, Simmons D, Taylor H, Thomas A, Weiss D, Hramiak I, Group At (2010) Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial. Lancet 376(9739):419–430CrossRef Ismail-Beigi F, Craven T, Banerji MA, Basile J, Calles J, Cohen RM, Cuddihy R, Cushman WC, Genuth S, Grimm RH, Hamilton BP, Hoogwerf B, Karl D, Katz L, Krikorian A, O’Connor P, Pop-Busui R, Schubart U, Simmons D, Taylor H, Thomas A, Weiss D, Hramiak I, Group At (2010) Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial. Lancet 376(9739):419–430CrossRef
9.
Zurück zum Zitat Barr EL, Zimmet PZ, Welborn TA, Jolley D, Magliano DJ, Dunstan DW, Cameron AJ, Dwyer T, Taylor HR, Tonkin AM, Wong TY, McNeil J, Shaw JE (2007) Risk of cardiovascular and all-cause mortality in individuals with diabetes mellitus, impaired fasting glucose, and impaired glucose tolerance: the Australian diabetes, obesity, and lifestyle study (AusDiab). Circulation 116(2):151–157CrossRef Barr EL, Zimmet PZ, Welborn TA, Jolley D, Magliano DJ, Dunstan DW, Cameron AJ, Dwyer T, Taylor HR, Tonkin AM, Wong TY, McNeil J, Shaw JE (2007) Risk of cardiovascular and all-cause mortality in individuals with diabetes mellitus, impaired fasting glucose, and impaired glucose tolerance: the Australian diabetes, obesity, and lifestyle study (AusDiab). Circulation 116(2):151–157CrossRef
10.
Zurück zum Zitat DECODE Study Group, the European Diabetes Epidemiology Group (2001) Glucose tolerance and cardiovascular mortality: comparison of fasting and 2-hour diagnostic criteria. Arch Intern Med 161(3):397–405CrossRef DECODE Study Group, the European Diabetes Epidemiology Group (2001) Glucose tolerance and cardiovascular mortality: comparison of fasting and 2-hour diagnostic criteria. Arch Intern Med 161(3):397–405CrossRef
11.
Zurück zum Zitat Gohbara M, Iwahashi N, Sato R, Akiyama E, Konishi M, Nakahashi H, Kataoka S, Takahashi H, Kirigaya J, Minamimoto Y, Okada K, Matsuzawa Y, Maejima N, Hibi K, Kosuge M, Ebina T, Sugano T, Ishikawa T, Tamura K, Kimura K (2021) Skeletal muscle mass is associated with glycemic variability in patients with ST-segment elevation myocardial infarction. Heart Vessels 36(7):945–954CrossRef Gohbara M, Iwahashi N, Sato R, Akiyama E, Konishi M, Nakahashi H, Kataoka S, Takahashi H, Kirigaya J, Minamimoto Y, Okada K, Matsuzawa Y, Maejima N, Hibi K, Kosuge M, Ebina T, Sugano T, Ishikawa T, Tamura K, Kimura K (2021) Skeletal muscle mass is associated with glycemic variability in patients with ST-segment elevation myocardial infarction. Heart Vessels 36(7):945–954CrossRef
12.
Zurück zum Zitat Huang Y, Cai X, Mai W, Li M, Hu Y (2016) Association between prediabetes and risk of cardiovascular disease and all cause mortality: systematic review and meta-analysis. BMJ 355:i5953CrossRef Huang Y, Cai X, Mai W, Li M, Hu Y (2016) Association between prediabetes and risk of cardiovascular disease and all cause mortality: systematic review and meta-analysis. BMJ 355:i5953CrossRef
13.
Zurück zum Zitat Selvin E, Wang D, McEvoy JW, Juraschek SP, Lazo M, Hamet P, Cooper ME, Marre M, Williams B, Harrap S, Chalmers J, Woodward M (2019) Response of 1,5-anhydroglucitol level to intensive glucose- and blood-pressure lowering interventions, and its associations with clinical outcomes in the ADVANCE trial. Diabetes Obes Metab 21(8):2017–2023. https://doi.org/10.1111/dom.13755CrossRef Selvin E, Wang D, McEvoy JW, Juraschek SP, Lazo M, Hamet P, Cooper ME, Marre M, Williams B, Harrap S, Chalmers J, Woodward M (2019) Response of 1,5-anhydroglucitol level to intensive glucose- and blood-pressure lowering interventions, and its associations with clinical outcomes in the ADVANCE trial. Diabetes Obes Metab 21(8):2017–2023. https://​doi.​org/​10.​1111/​dom.​13755CrossRef
15.
Zurück zum Zitat Levitan EB, Song Y, Ford ES, Liu S (2004) Is nondiabetic hyperglycemia a risk factor for cardiovascular disease? a meta-analysis of prospective studies. Arch Intern Med 164(19):2147–2155CrossRef Levitan EB, Song Y, Ford ES, Liu S (2004) Is nondiabetic hyperglycemia a risk factor for cardiovascular disease? a meta-analysis of prospective studies. Arch Intern Med 164(19):2147–2155CrossRef
16.
Zurück zum Zitat Kawano H, Motoyama T, Hirashima O, Hirai N, Miyao Y, Sakamoto T, Kugiyama K, Ogawa H, Yasue H (1999) Hyperglycemia rapidly suppresses flow-mediated endothelium-dependent vasodilation of brachial artery. J Am Coll Cardiol 34(1):146–154CrossRef Kawano H, Motoyama T, Hirashima O, Hirai N, Miyao Y, Sakamoto T, Kugiyama K, Ogawa H, Yasue H (1999) Hyperglycemia rapidly suppresses flow-mediated endothelium-dependent vasodilation of brachial artery. J Am Coll Cardiol 34(1):146–154CrossRef
17.
Zurück zum Zitat Williams SB, Goldfine AB, Timimi FK, Ting HH, Roddy MA, Simonson DC, Creager MA (1998) Acute hyperglycemia attenuates endothelium-dependent vasodilation in humans in vivo. Circulation 97(17):1695–1701CrossRef Williams SB, Goldfine AB, Timimi FK, Ting HH, Roddy MA, Simonson DC, Creager MA (1998) Acute hyperglycemia attenuates endothelium-dependent vasodilation in humans in vivo. Circulation 97(17):1695–1701CrossRef
18.
Zurück zum Zitat Stettler C, Stahl M, Allemann S, Diem P, Schmidlin K, Zwahlen M, Riesen W, Keller U, Christ E (2008) Association of 1,5-anhydroglucitol and 2-h postprandial blood glucose in type 2 diabetic patients. Diabetes Care 31(8):1534–1535CrossRef Stettler C, Stahl M, Allemann S, Diem P, Schmidlin K, Zwahlen M, Riesen W, Keller U, Christ E (2008) Association of 1,5-anhydroglucitol and 2-h postprandial blood glucose in type 2 diabetic patients. Diabetes Care 31(8):1534–1535CrossRef
19.
Zurück zum Zitat Yamanouchi T, Ogata N, Tagaya T, Kawasaki T, Sekino N, Funato H, Akaoka L, Miyashita H (1996) Clinical usefulness of serum 1,5-anhydroglucitol in monitoring glycaemic control. Lancet 347(9014):1514–1518CrossRef Yamanouchi T, Ogata N, Tagaya T, Kawasaki T, Sekino N, Funato H, Akaoka L, Miyashita H (1996) Clinical usefulness of serum 1,5-anhydroglucitol in monitoring glycaemic control. Lancet 347(9014):1514–1518CrossRef
20.
Zurück zum Zitat Liang M, McEvoy JW, Chen Y, Sharrett AR, Selvin E (2016) Association of a biomarker of glucose peaks, 1,5-anhydroglucitol. Subclinical Cardiovasc Dis Diabetes Care 39(10):1752–1759CrossRef Liang M, McEvoy JW, Chen Y, Sharrett AR, Selvin E (2016) Association of a biomarker of glucose peaks, 1,5-anhydroglucitol. Subclinical Cardiovasc Dis Diabetes Care 39(10):1752–1759CrossRef
21.
Zurück zum Zitat Selvin E, Rawlings A, Lutsey P, Maruthur N, Pankow JS, Steffes M, Coresh J (2016) Association of 1,5-anhydroglucitol with cardiovascular disease and mortality. Diabetes 65(1):201–208CrossRef Selvin E, Rawlings A, Lutsey P, Maruthur N, Pankow JS, Steffes M, Coresh J (2016) Association of 1,5-anhydroglucitol with cardiovascular disease and mortality. Diabetes 65(1):201–208CrossRef
22.
Zurück zum Zitat Ouchi S, Shimada K, Miyazaki T, Takahashi S, Sugita Y, Shimizu M, Murata A, Kadoguchi T, Kato T, Aikawa T, Suda S, Sai E, Hiki M, Iwata H, Kasai T, Miyauchi K, Daida H (2017) Low 1,5-anhydroglucitol levels are associated with long-term cardiac mortality in acute coronary syndrome patients with hemoglobin A1c levels less than 7.0. Cardiovasc Diabetol 16(1):151CrossRef Ouchi S, Shimada K, Miyazaki T, Takahashi S, Sugita Y, Shimizu M, Murata A, Kadoguchi T, Kato T, Aikawa T, Suda S, Sai E, Hiki M, Iwata H, Kasai T, Miyauchi K, Daida H (2017) Low 1,5-anhydroglucitol levels are associated with long-term cardiac mortality in acute coronary syndrome patients with hemoglobin A1c levels less than 7.0. Cardiovasc Diabetol 16(1):151CrossRef
23.
Zurück zum Zitat Takahashi S, Shimada K, Miyauchi K, Miyazaki T, Sai E, Ogita M, Tsuboi S, Tamura H, Okazaki S, Shiozawa T, Ouchi S, Aikawa T, Kadoguchi T, Al Shahi H, Yoshihara T, Hiki M, Isoda K, Daida H (2016) Low and exacerbated levels of 1,5-anhydroglucitol are associated with cardiovascular events in patients after first-time elective percutaneous coronary intervention. Cardiovasc Diabetol 15(1):145CrossRef Takahashi S, Shimada K, Miyauchi K, Miyazaki T, Sai E, Ogita M, Tsuboi S, Tamura H, Okazaki S, Shiozawa T, Ouchi S, Aikawa T, Kadoguchi T, Al Shahi H, Yoshihara T, Hiki M, Isoda K, Daida H (2016) Low and exacerbated levels of 1,5-anhydroglucitol are associated with cardiovascular events in patients after first-time elective percutaneous coronary intervention. Cardiovasc Diabetol 15(1):145CrossRef
24.
Zurück zum Zitat Dungan KM, Buse JB, Largay J, Kelly MM, Button EA, Kato S, Wittlin S (2006) 1,5-anhydroglucitol and postprandial hyperglycemia as measured by continuous glucose monitoring system in moderately controlled patients with diabetes. Diabetes Care 29(6):1214–1219CrossRef Dungan KM, Buse JB, Largay J, Kelly MM, Button EA, Kato S, Wittlin S (2006) 1,5-anhydroglucitol and postprandial hyperglycemia as measured by continuous glucose monitoring system in moderately controlled patients with diabetes. Diabetes Care 29(6):1214–1219CrossRef
25.
Zurück zum Zitat Mook-Kanamori DO, Selim MM, Takiddin AH, Al-Homsi H, Al-Mahmoud KA, Al-Obaidli A, Zirie MA, Rowe J, Yousri NA, Karoly ED, Kocher T, SekkalGherbi W, Chidiac OM, Mook-Kanamori MJ, Abdul Kader S, Al Muftah WA, McKeon C, Suhre K (2014) 1,5-Anhydroglucitol in saliva is a noninvasive marker of short-term glycemic control. J Clin Endocrinol Metab 99(3):E479-483CrossRef Mook-Kanamori DO, Selim MM, Takiddin AH, Al-Homsi H, Al-Mahmoud KA, Al-Obaidli A, Zirie MA, Rowe J, Yousri NA, Karoly ED, Kocher T, SekkalGherbi W, Chidiac OM, Mook-Kanamori MJ, Abdul Kader S, Al Muftah WA, McKeon C, Suhre K (2014) 1,5-Anhydroglucitol in saliva is a noninvasive marker of short-term glycemic control. J Clin Endocrinol Metab 99(3):E479-483CrossRef
26.
Zurück zum Zitat Won JC, Park CY, Park HS, Kim JH, Choi ES, Rhee EJ, Lee WY, Oh KW, Kim SW, Park SW (2009) 1,5-Anhydroglucitol reflects postprandial hyperglycemia and a decreased insulinogenic index, even in subjects with prediabetes and well-controlled type 2 diabetes. Diabetes Res Clin Pract 84(1):51–57CrossRef Won JC, Park CY, Park HS, Kim JH, Choi ES, Rhee EJ, Lee WY, Oh KW, Kim SW, Park SW (2009) 1,5-Anhydroglucitol reflects postprandial hyperglycemia and a decreased insulinogenic index, even in subjects with prediabetes and well-controlled type 2 diabetes. Diabetes Res Clin Pract 84(1):51–57CrossRef
27.
Zurück zum Zitat Sianos G, Morel MA, Kappetein AP, Morice MC, Colombo A, Dawkins K, van den Brand M, Van Dyck N, Russell ME, Mohr FW, Serruys PW (2005) The SYNTAX Score: an angiographic tool grading the complexity of coronary artery disease. EuroIntervention 1(2):219–227 Sianos G, Morel MA, Kappetein AP, Morice MC, Colombo A, Dawkins K, van den Brand M, Van Dyck N, Russell ME, Mohr FW, Serruys PW (2005) The SYNTAX Score: an angiographic tool grading the complexity of coronary artery disease. EuroIntervention 1(2):219–227
28.
Zurück zum Zitat Morishita T, Uzui H, Nakano A, Fukuoka Y, Ikeda H, Amaya N, Kaseno K, Ishida K, Lee JD, Tada H (2018) Association of plasma pentraxin-3 levels with coronary risk factors and the lipid profile: a cross-sectional study in Japanese patients with stable angina pectoris. Heart Vessels 33(11):1301–1310CrossRef Morishita T, Uzui H, Nakano A, Fukuoka Y, Ikeda H, Amaya N, Kaseno K, Ishida K, Lee JD, Tada H (2018) Association of plasma pentraxin-3 levels with coronary risk factors and the lipid profile: a cross-sectional study in Japanese patients with stable angina pectoris. Heart Vessels 33(11):1301–1310CrossRef
29.
Zurück zum Zitat Thygesen K, Alpert JS, Jaffe AS, Simoons ML, Chaitman BR, White HD, Katus HA, Lindahl B, Morrow DA, Clemmensen PM, Johanson P, Hod H, Underwood R, Bax JJ, Bonow RO, Pinto F, Gibbons RJ, Fox KA, Atar D, Newby LK, Galvani M, Hamm CW, Uretsky BF, Steg PG, Wijns W, Bassand JP, Menasché P, Ravkilde J, Ohman EM, Antman EM, Wallentin LC, Armstrong PW, Januzzi JL, Nieminen MS, Gheorghiade M, Filippatos G, Luepker RV, Fortmann SP, Rosamond WD, Levy D, Wood D, Smith SC, Hu D, Lopez-Sendon JL, Robertson RM, Weaver D, Tendera M, Bove AA, Parkhomenko AN, Vasilieva EJ, Mendis S, Infarction JEAAWTFftUDoM (2012) Third universal definition of myocardial infarction. Circulation 126(16):2020–2035CrossRef Thygesen K, Alpert JS, Jaffe AS, Simoons ML, Chaitman BR, White HD, Katus HA, Lindahl B, Morrow DA, Clemmensen PM, Johanson P, Hod H, Underwood R, Bax JJ, Bonow RO, Pinto F, Gibbons RJ, Fox KA, Atar D, Newby LK, Galvani M, Hamm CW, Uretsky BF, Steg PG, Wijns W, Bassand JP, Menasché P, Ravkilde J, Ohman EM, Antman EM, Wallentin LC, Armstrong PW, Januzzi JL, Nieminen MS, Gheorghiade M, Filippatos G, Luepker RV, Fortmann SP, Rosamond WD, Levy D, Wood D, Smith SC, Hu D, Lopez-Sendon JL, Robertson RM, Weaver D, Tendera M, Bove AA, Parkhomenko AN, Vasilieva EJ, Mendis S, Infarction JEAAWTFftUDoM (2012) Third universal definition of myocardial infarction. Circulation 126(16):2020–2035CrossRef
30.
Zurück zum Zitat Vickers AJ, Elkin EB (2006) Decision curve analysis: a novel method for evaluating prediction models. Med Decis Mak 26(6):565–574CrossRef Vickers AJ, Elkin EB (2006) Decision curve analysis: a novel method for evaluating prediction models. Med Decis Mak 26(6):565–574CrossRef
31.
Zurück zum Zitat Kanda Y (2013) Investigation of the freely available easy-to-use software “EZR” for medical statistics. Bone Marrow Transplant 48(3):452–458CrossRef Kanda Y (2013) Investigation of the freely available easy-to-use software “EZR” for medical statistics. Bone Marrow Transplant 48(3):452–458CrossRef
32.
Zurück zum Zitat Mukai N, Ninomiya T, Hata J, Hirakawa Y, Ikeda F, Fukuhara M, Hotta T, Koga M, Nakamura U, Kang D, Kitazono T, Kiyohara Y (2015) Association of hemoglobin A1c and glycated albumin with carotid atherosclerosis in community-dwelling Japanese subjects: the Hisayama Study. Cardiovasc Diabetol 14:84CrossRef Mukai N, Ninomiya T, Hata J, Hirakawa Y, Ikeda F, Fukuhara M, Hotta T, Koga M, Nakamura U, Kang D, Kitazono T, Kiyohara Y (2015) Association of hemoglobin A1c and glycated albumin with carotid atherosclerosis in community-dwelling Japanese subjects: the Hisayama Study. Cardiovasc Diabetol 14:84CrossRef
33.
Zurück zum Zitat Watanabe M, Kokubo Y, Higashiyama A, Ono Y, Miyamoto Y, Okamura T (2011) Serum 1,5-anhydro-d-glucitol levels predict first-ever cardiovascular disease: an 11-year population-based cohort study in Japan, the Suita study. Atherosclerosis 216(2):477–483CrossRef Watanabe M, Kokubo Y, Higashiyama A, Ono Y, Miyamoto Y, Okamura T (2011) Serum 1,5-anhydro-d-glucitol levels predict first-ever cardiovascular disease: an 11-year population-based cohort study in Japan, the Suita study. Atherosclerosis 216(2):477–483CrossRef
34.
Zurück zum Zitat Ikeda N, Hara H, Hiroi Y, Nakamura M (2016) Impact of serum 1,5-anhydro-d-glucitol level on prediction of major adverse cardiac and cerebrovascular events in non-diabetic patients without coronary artery disease. Atherosclerosis 253:1–6CrossRef Ikeda N, Hara H, Hiroi Y, Nakamura M (2016) Impact of serum 1,5-anhydro-d-glucitol level on prediction of major adverse cardiac and cerebrovascular events in non-diabetic patients without coronary artery disease. Atherosclerosis 253:1–6CrossRef
35.
Zurück zum Zitat Serruys PW, Morice MC, Kappetein AP, Colombo A, Holmes DR, Mack MJ, Ståhle E, Feldman TE, van den Brand M, Bass EJ, Van Dyck N, Leadley K, Dawkins KD, Mohr FW, Investigators S (2009) Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease. N Engl J Med 360(10):961–972CrossRef Serruys PW, Morice MC, Kappetein AP, Colombo A, Holmes DR, Mack MJ, Ståhle E, Feldman TE, van den Brand M, Bass EJ, Van Dyck N, Leadley K, Dawkins KD, Mohr FW, Investigators S (2009) Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease. N Engl J Med 360(10):961–972CrossRef
Metadaten
Titel
Prognostic value of 1,5-anhydro-d-glucitol incorporating syntax score in acute coronary syndrome
verfasst von
Tetsuji Morishita
Hiroyasu Uzui
Yasuhiko Mitsuke
Hiroshi Tada
Publikationsdatum
07.07.2022
Verlag
Springer Japan
Erschienen in
Heart and Vessels / Ausgabe 1/2023
Print ISSN: 0910-8327
Elektronische ISSN: 1615-2573
DOI
https://doi.org/10.1007/s00380-022-02126-8

Weitere Artikel der Ausgabe 1/2023

Heart and Vessels 1/2023 Zur Ausgabe

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.